Provided by Tiger Trade Technology Pte. Ltd.

Veradermics, Inc.

108.68
+6.266.11%
Pre-market: 108.810.1300+0.12%05:41 EDT
Volume:766.55K
Turnover:83.04M
Market Cap:4.54B
PE:-16.87
High:109.74
Open:105.56
Low:102.83
Close:102.42
52wk High:131.24
52wk Low:32.00
Shares:41.78M
Float Shares:32.29M
Volume Ratio:1.13
T/O Rate:2.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4439
EPS(LYR):-111.9114
ROE:-72.06%
ROA:-43.45%
PB:5.58
PE(LYR):-0.97

Loading ...

Veradermics to Present Age-subgroup Data from Vdphl01 Male Hair Loss Trial at AAD Innovation Academy

Reuters
·
Jul 17

S&P 500 Futures Fall in Premarket Trading; Elbit Systems, Maase Lead

Dow Jones
·
Jul 17

Veradermics is Maintained at Buy by Citigroup

Dow Jones
·
Jul 17

Veradermics, Incorporated (MANE) Gets a Buy from Jefferies

TIPRANKS
·
Jul 16

Veradermics price target raised to $160 from $135 at Citi

TIPRANKS
·
Jul 16

Veradermics Inc : Citigroup Raises Target Price to $160 from $135

THOMSON REUTERS
·
Jul 16

Sector Update: Healthcare

MT Newswires Live
·
Jul 16

B. Riley Analyst Initiates Coverage of Veradermics Stock (MANE) With a Buy Rating

TIPRANKS
·
Jul 16

Veradermics Shares Gain Nearly 14% After Oral Hair Loss Drug Shows Positive Mid-stage Data in Women

THOMSON REUTERS
·
Jul 15

Veradermics rises 13.9%

TIPRANKS
·
Jul 15

Veradermics Shares Rise After Positive Midstage Hair-loss Trial Results

Dow Jones
·
Jul 15

Positive Phase II Trial Results Announced for Veradermics' Female Hair Loss Treatment

Deep News
·
Jul 15

B. Riley Initiates Veradermics at Buy With $170 Price Target

MT Newswires Live
·
Jul 15

U.S. Stocks on the Move-johnson & Johnson, Blackrock, Veradermics

Reuters
·
Jul 15

Veradermics' Potential Female Hair Loss Treatment Restores Hair in Phase 2 Trial

MT Newswires Live
·
Jul 15

Veradermics Rises as Oral Hair Loss Drug Shows Positive Mid-stage Data in Women

Reuters
·
Jul 15

Veradermics announces results from Phase 2 trial of VDPHL01

TIPRANKS
·
Jul 15

Veradermics’ Oral Vdphl01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout

THOMSON REUTERS
·
Jul 15

Veradermics - Vdphl01 Shows Favorable Safety with no Treatment-related Serious Adverse Events or Cardiac Aesis

THOMSON REUTERS
·
Jul 15

Veradermics - Vdphl01 Shows 88.9%-90% Improvement in Hair Coverage at Month 6 in Phase 2 Study

THOMSON REUTERS
·
Jul 15